Adult ADHD - Therapeutic Opportunities

Questions: Discounts, Updates etc.

Price: $1,900.00

Publication Date: 2004-03-18

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

With the recent medical classification of adult ADHD and potentially twice the number of patients compared to pediatric ADHD, manufacturers are seeking new indications in this expanding and lucrative market. Lilly�s Strattera was the first drug to exploit this, and is forecast to reach blockbuster status by 2006. Consequently, manufacturers will need to differentiate their products from Strattera.


Scope

  • Overview of the epidemiology of adult ADHD, with an assessment of the untapped patient potential
  • Discussion of the problems facing physicians in the diagnosis of adult ADHD
  • Analysis of the current market leaders and primary contenders for market entry, with adult ADHD-specific market forecasts
  • Exploration of product positioning and life-cycle management strategies currently used by Strattera, Adderall XR and Concerta


    • Report Highlights
    Strattera was the first drug approved for the treatment of adult ADHD in November 2002. Since launch Strattera has a steady sales increase from $55m in Q1 2003 to $133m in Q4 2003, and Datamonitor has forecast Strattera to reach blockbuster status by 2006.

    Shire�s Adderall XR recently received an approvable letter from the FDA for adult ADHD and J&J�s Concerta is currently in Phase III with an expected launch in 2005. Datamonitor forecasts that both drugs will see an increase in sales from gaining an indication for this market, although both will also experience a decline in revenues post 2005.

    Approximately 75% of adults with ADHD present with a comorbid condition, of which anxiety and depressive disorders predominate. Datamonitor has highlighted two drug classes, which may benefit from further investigation of the treatment of such comorbidities in order to increase their market share in the adult ADHD market.


    Reasons to Purchase

  • Analyze the commercial viability of the adult ADHD market, based on estimated patient numbers
  • Develop market entry and consolidation strategies through an understanding of key unmet needs in the market
  • Identify and assess novel R&D compounds in the adult ADHD pipeline

    • Table of Contents

    Other users found this report page using the following search terms: adhd attention deficit adult adhd strattera concerta treatment adderall adults guidelines sales market

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.